Latin America Conjugate Vaccine Market (2018-2023)
The report is sent in 5-10 business days after order is placed.
Latin America Conjugate Vaccine Market:
Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. Latin America is a market with a significant growth rate for conjugate vaccines. The conjugate vaccine market in Latin America is expected to grow at a CAGR of 20.4% leading to revenue of USD 5.43 Bn by 2023. By volume, it is anticipated to reach 839.21 Million units by 2023, expanding at a CAGR of 20.19%.
Countries in the Americas have been among the first few developing nations to introduce pneumococcal conjugate vaccines into their Expanded Programs on Immunization, with 34 countries and territories having introduced these vaccines as of September 2015.
Market Segmentation:
Latin America has a growing market owing to increase in the incidence of chronic diseases, government initiatives, and control strategies.
Threats and key players:
1. Overview of the Latin America conjugate vaccine market
2. Market drivers, and challenges in the Latin America conjugate vaccine market
3. Market trends in Latin America conjugate vaccine market
4. Historical, current and forecasted market size data for Latin America based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for Latin America by end user (paediatric and adult conjugate vaccines) – by revenue and by volume
6. Historical, current and forecasted market size data of conjugate vaccines by countries (Brazil, Argentina and the Rest of LATAM) – by revenue and by volume
7. Historical, current and forecasted market size data for country-wise segments – by revenue and by volume
8. Analysis of the competitive landscape and profiles of major competitors operating in the Latin American market
Why buy?
With the given market data, Netscribes offers customizations according to specific needs.
Latin America Conjugate Vaccine Market:
Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. Latin America is a market with a significant growth rate for conjugate vaccines. The conjugate vaccine market in Latin America is expected to grow at a CAGR of 20.4% leading to revenue of USD 5.43 Bn by 2023. By volume, it is anticipated to reach 839.21 Million units by 2023, expanding at a CAGR of 20.19%.
Countries in the Americas have been among the first few developing nations to introduce pneumococcal conjugate vaccines into their Expanded Programs on Immunization, with 34 countries and territories having introduced these vaccines as of September 2015.
Market Segmentation:
- Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type B, diphtheria-tetanus-pertussis, meningococcal and others.
- Based on end user, the market is segmented into paediatric and adult.
- By countries, the Latin American market is divided into Brazil, Argentina and the Rest of LATAM.
Latin America has a growing market owing to increase in the incidence of chronic diseases, government initiatives, and control strategies.
Threats and key players:
- The Latin America Conjugate Vaccine market is expected to grow positively. There are still a lot of gaps to be filled for a higher penetration of such vaccines among the masses. A dearth of data on Hib disease burden and limited awareness of Hib disease has resulted in a lack of advocacy for the introduction of Hib vaccine in some countries. Highly complicated manufacturing processes, pricing inefficiencies and lack of accessibility are some of the major obstacles in the growth path, which need to be addressed.
- Conjugate Vaccine providers operating in the market are Pfizer Inc., Merck, Novartis, Sanofi Pasteur, CSL Limited, etc.
1. Overview of the Latin America conjugate vaccine market
2. Market drivers, and challenges in the Latin America conjugate vaccine market
3. Market trends in Latin America conjugate vaccine market
4. Historical, current and forecasted market size data for Latin America based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for Latin America by end user (paediatric and adult conjugate vaccines) – by revenue and by volume
6. Historical, current and forecasted market size data of conjugate vaccines by countries (Brazil, Argentina and the Rest of LATAM) – by revenue and by volume
7. Historical, current and forecasted market size data for country-wise segments – by revenue and by volume
8. Analysis of the competitive landscape and profiles of major competitors operating in the Latin American market
Why buy?
- Understand the demand for conjugate vaccines to determine the viability of the market
- Understand the country-specific market size and observations for each segment
- Develop strategies based on the drivers, trends and highlights for each of the segments
- Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
- Recognize the key competitors of this market and respond accordingly
- Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
- Define the competitive positioning by comparing the products and services with the key players in the market
With the given market data, Netscribes offers customizations according to specific needs.
CHAPTER 1: EXECUTIVE SUMMARY
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary I
1.4 Executive summary II
CHAPTER 2: MARKET OVERVIEW
2.1. Market definitions
2.2. Latin America market overview – by revenue
Latin America historical (2015-2017) market revenue (USD Bn)
Latin America forecasted (2018-2023) market revenue (USD Bn)
Country-wise market (2018-2023) revenue (USD Bn)
2.3. Latin America market overview – by volume
Latin America historical (2015-2017) market volume (Million units)
Latin America forecasted (2018-2023) market volume (Million units)
Country-wise (2018-2023) market volume (Million units)
2.4. Latin America market drivers and challenges
2.4.1. Latin America market drivers
2.4.2. Latin America market challenges
2.5. Latin America market trends
2.6. Value chain
2.7.1. Country-specific market overview – Brazil
Observation
Key competitors
2.7.1(A) Country-specific market overview – Brazil by revenue and by volume
Brazil historical (2015-2017) market revenue (USD Bn)
Brazil forecasted (2018-2023) market revenue (USD Bn)
Brazil historical (2015-2017) market volume (Million units)
Brazil forecasted (2018-2023) market volume (Million units)
2.7.2. Country-specific market overview – Argentina
Observation
Key competitors
2.7.2(A) Country-specific market overview – Argentina by revenue and by volume
Argentina historical (2015-2017) market revenue (USD Bn)
Argentina forecasted (2018-2023) market revenue (USD Bn)
Argentina historical (2015-2017) market volume (Million units)
Argentina forecasted (2018-2023) market volume (Million units)
2.7.3. Country-specific market overview – Rest of LATAM
Observation
Key competitors
2.7.3(A) Country-specific market overview – Rest of LATAM by revenue and by volume
Rest of LATAM historical (2015-2017) market revenue (USD Bn)
Rest of LATAM forecasted (2018-2023) market revenue (USD Bn)
Rest of LATAM historical (2015-2017) market volume (Million units)
Rest of LATAM forecasted (2018-2023) market volume (Million units)
CHAPTER 3: LATIN AMERICA MAJOR SEGMENT OVERVIEW BY DISEASE INDICATION
3.1. Disease indication: Pneumococcal, Hib by revenue, by volume, CAGR
Overview by disease indication
Market share (2015, 2018 & 2023): Pneumococcal – Latin America (USD Bn, Million units)
Market share (2015, 2018 & 2023): Hib – Latin America (USD Bn, Million units)
3.2. Disease indication: DTP, Meningococcal by revenue, by volume, CAGR
Overview by disease indication
Market share (2015, 2018 & 2023): DTP – Latin America (USD Bn, Million units)
Market share (2015, 2018 & 2023): Meningococcal – Latin America (USD Bn, Million units)
CHAPTER 4: LATIN AMERICA MAJOR SEGMENT OVERVIEW BY END USER
4.1. End-user: Pediatric, Adult by revenue, by volume, CAGR
Overview by end user
Market share (2015, 2018 & 2023): Paediatric – Latin America (USD Bn, Million units)
Market share (2015, 2018 & 2023): Adult – Latin America (USD Bn, Million units)
CHAPTER 5: BRAZIL – BY DISEASE INDICATION
5.1. Brazil: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.2. Brazil: disease indication Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.3. Brazil: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.4. Brazil: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 6: BRAZIL – BY END USER
6.1. Brazil: end user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 7: ARGENTINA – BY DISEASE INDICATION
7.1. Argentina: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.2. Argentina: disease indication – Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.3. Argentina: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.4. Argentina: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 8: ARGENTINA – BY END USER
8.1. Argentina: end user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 9: REST OF LATAM – BY DISEASE INDICATION
9.1. Rest of LATAM: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
9.2. Rest of LATAM: disease indication – Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
9.3. Rest of LATAM: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
9.4. Rest of LATAM: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 10: REST OF LATAM – BY END USER
10.1. Rest of LATAM: end user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 11: COMPETITIVE LANDSCAPE
11.1. Company market share
Top 5 companies
11.2. Company overview – Pfizer Inc.
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.2(A) Executive profile Pfizer Inc.
11.3. Company overview – Merck & Co.
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.3(A) Executive profile Merck & Co.
11.4. Company overview – Novartis
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.4(A) Executive profile Novartis
11.5. Company overview – Sanofi Pasteur
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.5(A) Executive profile Sanofi Pasteur
11.6. Company overview – CSL Limited
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.6(A) Executive profile CSL Limited
Appendix
List of tables
Assumptions
Conclusion
Research and methodology
About Netscribes Inc.
Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary I
1.4 Executive summary II
CHAPTER 2: MARKET OVERVIEW
2.1. Market definitions
2.2. Latin America market overview – by revenue
Latin America historical (2015-2017) market revenue (USD Bn)
Latin America forecasted (2018-2023) market revenue (USD Bn)
Country-wise market (2018-2023) revenue (USD Bn)
2.3. Latin America market overview – by volume
Latin America historical (2015-2017) market volume (Million units)
Latin America forecasted (2018-2023) market volume (Million units)
Country-wise (2018-2023) market volume (Million units)
2.4. Latin America market drivers and challenges
2.4.1. Latin America market drivers
2.4.2. Latin America market challenges
2.5. Latin America market trends
2.6. Value chain
2.7.1. Country-specific market overview – Brazil
Observation
Key competitors
2.7.1(A) Country-specific market overview – Brazil by revenue and by volume
Brazil historical (2015-2017) market revenue (USD Bn)
Brazil forecasted (2018-2023) market revenue (USD Bn)
Brazil historical (2015-2017) market volume (Million units)
Brazil forecasted (2018-2023) market volume (Million units)
2.7.2. Country-specific market overview – Argentina
Observation
Key competitors
2.7.2(A) Country-specific market overview – Argentina by revenue and by volume
Argentina historical (2015-2017) market revenue (USD Bn)
Argentina forecasted (2018-2023) market revenue (USD Bn)
Argentina historical (2015-2017) market volume (Million units)
Argentina forecasted (2018-2023) market volume (Million units)
2.7.3. Country-specific market overview – Rest of LATAM
Observation
Key competitors
2.7.3(A) Country-specific market overview – Rest of LATAM by revenue and by volume
Rest of LATAM historical (2015-2017) market revenue (USD Bn)
Rest of LATAM forecasted (2018-2023) market revenue (USD Bn)
Rest of LATAM historical (2015-2017) market volume (Million units)
Rest of LATAM forecasted (2018-2023) market volume (Million units)
CHAPTER 3: LATIN AMERICA MAJOR SEGMENT OVERVIEW BY DISEASE INDICATION
3.1. Disease indication: Pneumococcal, Hib by revenue, by volume, CAGR
Overview by disease indication
Market share (2015, 2018 & 2023): Pneumococcal – Latin America (USD Bn, Million units)
Market share (2015, 2018 & 2023): Hib – Latin America (USD Bn, Million units)
3.2. Disease indication: DTP, Meningococcal by revenue, by volume, CAGR
Overview by disease indication
Market share (2015, 2018 & 2023): DTP – Latin America (USD Bn, Million units)
Market share (2015, 2018 & 2023): Meningococcal – Latin America (USD Bn, Million units)
CHAPTER 4: LATIN AMERICA MAJOR SEGMENT OVERVIEW BY END USER
4.1. End-user: Pediatric, Adult by revenue, by volume, CAGR
Overview by end user
Market share (2015, 2018 & 2023): Paediatric – Latin America (USD Bn, Million units)
Market share (2015, 2018 & 2023): Adult – Latin America (USD Bn, Million units)
CHAPTER 5: BRAZIL – BY DISEASE INDICATION
5.1. Brazil: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.2. Brazil: disease indication Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.3. Brazil: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.4. Brazil: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 6: BRAZIL – BY END USER
6.1. Brazil: end user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 7: ARGENTINA – BY DISEASE INDICATION
7.1. Argentina: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.2. Argentina: disease indication – Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.3. Argentina: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.4. Argentina: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 8: ARGENTINA – BY END USER
8.1. Argentina: end user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 9: REST OF LATAM – BY DISEASE INDICATION
9.1. Rest of LATAM: disease indication Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
9.2. Rest of LATAM: disease indication – Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
9.3. Rest of LATAM: disease indication Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
9.4. Rest of LATAM: disease indication Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
CHAPTER 10: REST OF LATAM – BY END USER
10.1. Rest of LATAM: end user Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
CHAPTER 11: COMPETITIVE LANDSCAPE
11.1. Company market share
Top 5 companies
11.2. Company overview – Pfizer Inc.
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.2(A) Executive profile Pfizer Inc.
11.3. Company overview – Merck & Co.
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.3(A) Executive profile Merck & Co.
11.4. Company overview – Novartis
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.4(A) Executive profile Novartis
11.5. Company overview – Sanofi Pasteur
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.5(A) Executive profile Sanofi Pasteur
11.6. Company overview – CSL Limited
Company snapshot
Product offerings
Growth strategies
Initiatives
Geographical presence
11.6(A) Executive profile CSL Limited
Appendix
List of tables
Assumptions
Conclusion
Research and methodology
About Netscribes Inc.
Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research
